Copeptin as a biomarker in cardiac disease

Current Topics in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 231-240

  Giannopoulos, Georgios ^a,b   Deftereos, Spyridon ^a   Panagopoulou, Vasiliki ^a   Kossyvakis, Charalambos ^a   Kaoukis, Andreas ^a   Bouras, Georgios ^a   Pyrgakis, Vlassios ^a   Cleman, Michael W ^a,b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Cardiovascular disease; Copeptin; Heart failure; Myocardial infarction; Vasopressin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COPEPTIN; EDETIC ACID; TROPONIN; TROPONIN T; VASOPRESSIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DYSPNEA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; IMMUNOASSAY; PROGNOSIS; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX PAIN;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GLYCOPEPTIDES; HEART FAILURE; HUMANS; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS;

EID: 84877821085     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990088     Document Type: Review

References (36)

1. Nickel C.H., Bingisser R., Morgenthaler N.G. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med, 2012, 10, 7.
2. de Bree F.M. Trafficking of the vasopressin and oxytocin prohormone through the regulated secretory pathway. J Neuroendocrinol, 2000, 12, 589-94.
3. Robertson G.L. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am, 2001, 30, 671-94.
4. Fricker L.D., Das B., Angeletti R.H. Identification of the pH-dependent membrane anchor of carboxypeptidase E (EC 3.4.17.10). J Biol Chem, 1990, 255, 2476-82.
5. Eipper B.A., Stoffers D.A., Mains R.E. The biosynthesis of neuropeptides, peptide alpha-amidation. Ann Rev Neurosci, 1992, 15, 57-85.
6. Acher R., Chauvet J., Rouille Y. Dynamic processing of neuropeptides, sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci, 2002, 18, 223-8.
7. Rouille Y., Spang A., Chauvet J., Acher R. Evidence for distinct dibasic processing endopeptidases with Lys-Arg and Arg-Arg specificities in neurohypophysial secretory granules. Biochem Biophys Res Commun, 1992, 183, 128-37.
8. Robertson G.L., Mahr E.A., Athar S., Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest, 1973, 52, 2340-52.
9. Morgenthaler N.G., Struck J., Alonso C., Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem, 2006, 52, 112-9.
10. BRAHMS Copeptin KRYPTOR insert. http,//www.copeptin.com/acute-myocardial-infarction/ifu/ifu_828.050_en_R07_brahms-kryptor-copeptin.pdf. Accessed, 13/9/2012
11. BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain. NICE medical technology guidance. June 2011. http,//www.nice.org.uk/nicemedia/live/13495/54982/54982.pdf. Accessed, 28/9/2012.
12. General Protocol for RK-065-32 Copeptin (Human) RIA kit. Phoenix Pharmaceuticals, Belmont, CA, USA. http,//www.phoenixpeptide.com/catalog/repository/QCdata_RIK/RK-065-32.pdf. Accessed, 13/9/2012.
13. Khan S.Q., Dhillon O.S., O'Brien R.J., Struck J., Quinn P.A., Morgenthaler N.G., Squire I.B., Davies J.E., Bergmann A., Ng L.L. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction, Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation, 2007, 115, 2103-10.
14. Reichlin T., Hochholzer W., Stelzig C., Laule K., Freidank H., Morgenthaler N.G., Bergmann A., Potocki M., Noveanu M., Breidthardt T., Christ A., Boldanova T., Merki R., Schaub N., Bingisser R., Christ M., Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol, 2009, 54, 60-8.
15. Keller T., Tzikas S., Zeller T., Czyz E., Lillpopp L., Ojeda F.M., Roth A., Bickel C., Baldus S., Sinning C.R., Wild P.S., Lubos E., Peetz D., Kunde J., Hartmann O., Bergmann A., Post F., Lackner K.J., Genth-Zotz S., Nicaud V., Tiret L., Münzel T.F., Blankenberg S. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol, 2010, 55, 2096-106.
16. Karakas M., Januzzi J.L. Jr, Meyer J., Lee H., Schlett C.L., Truong Q.A., Rottbauer W., Bamberg F., Dasdemir S., Hoffmann U., Koenig W. Copeptin does not add diagnostic information to highsensitivity troponin T in lowto intermediate-risk patients with acute chest pain, results from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem, 2011, 57, 1137-45.
17. Potocki M., Reichlin T., Thalmann S., Zellweger C., Twerenbold R., Reiter M., Steuer S., Bassetti S., Drexler B., Stelzig C., Freese M., Winkler K., Haaf P., Balmelli C., Hochholzer W., Osswald S., Mueller C. Diagnostic and prognostic impact of copeptin and highsensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction. Heart, 2012, 98, 558-65.
18. Eggers K.M., Venge P., Lindahl B. High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta, 2012, 413, 1135-40.
19. Giannitsis E., Kehayova T., Vafaie M., Katus H.A. Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction. Clin Chem, 2011, 57, 1452-5.
20. Charpentier S., Maupas-Schwalm F., Cournot M., Elbaz M., Botella J.M., Lauque D. Combination of copeptin and troponin assays to rapidly rule out non-ST elevation myocardial infarction in the emergency department. Acad Emerg Med, 2012, 19, 517-24.
21. Narayan H., Dhillon O.S., Quinn P.A., Struck J., Squire I.B., Davies J.E., Ng L.L. C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction, Leicester Acute Myocardial Infarction Peptide II (LAMP II) study. Clin Sci (Lond), 2011, 121, 79-89.
22. Kelly D., Squire I.B., Khan S.Q., Quinn P., Struck J., Morgenthaler N.G., Davies J.E., Ng L.L. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail, 2008, 14, 739-45.
23. Mellbin L.G., Rydén L., Brismar K., Morgenthaler N.G., Ohrvik J., Catrina S.B. Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction, a report from the DIGAMI 2 trial. Diabetes Care, 2010, 33, 1604-6.
24. Voors A.A., von Haehling S., Anker S.D., Hillege H.L., Struck J., Hartmann O., Bergmann A., Squire I., van Veldhuisen D.J., Dickstein K., OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction, results from the OPTIMAAL study. Eur Heart J, 2009, 30, 1187-94.
25. Goldsmith S.R., Francis G.S., Cowley A.W. Jr, Levine T.B., Cohn J.N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol, 1983, 1, 1385-90.
26. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., Berl T., Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med, 1981, 305, 263-6.
27. Stoiser B., Mörtl D., Hülsmann M., Berger R., Struck J., Morgenthaler N.G., Bergmann A., Pacher R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest, 2006, 36, 771-8.
28. Gegenhuber A., Struck J., Dieplinger B., Poelz W., Pacher R., Morgenthaler N.G., Bergmann A., Haltmayer M., Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro- A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail, 2007, 13, 42-9.
29. Potocki M., Breidthardt T., Mueller A., Reichlin T., Socrates T., Arenja N., Reiter M., Morgenthaler N.G., Bergmann A., Noveanu M., Buser P.T., Mueller C. Copeptin and risk stratification in patients with acute dyspnea. Crit Care, 2010, 14, R213.
30. Maisel A., Xue Y., Shah K., Mueller C., Nowak R., Peacock W.F., Ponikowski P., Mockel M., Hogan C., Wu A.H., Richards M., Clopton P., Filippatos G.S., Di Somma S., Anand I.S., Ng L., Daniels L.B., Neath S.X., Christenson R., Potocki M., McCord J., Terracciano G., Kremastinos D., Hartmann O., von Haehling S., Bergmann A., Morgenthaler N.G., Anker S.D. Increased 90-day mortality in patients with acute heart failure with elevated copeptin, secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail, 2011, 4, 613-20.
31. Masson S., Latini R, Carbonieri E., Moretti L., Rossi M.G., Ciricugno S., Milani V., Marchioli R., Struck J., Bergmann A., Maggioni A.P., Tognoni G., Tavazzi L., GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure, data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail, 2010, 12, 338-47.
32. Alehagen U., Dahlström U., Rehfeld J.F., Goetze J.P. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA, 2011, 305, 2088-95.
33. Neuhold S., Huelsmann M., Strunk G., Stoiser B., Struck J., Morgenthaler N.G., Bergmann A., Moertl D., Berger R., Pacher R. Comparison of copeptin, B-type natriuretic peptide, and aminoterminal pro-B-type natriuretic peptide in patients with chronic heart failure, prediction of death at different stages of the disease. J Am Coll Cardiol, 2008, 52, 266-72.
34. Tentzeris I., Jarai R., Farhan S., Perkmann T., Schwarz M.A., Jakl G., Wojta J., Huber K. Complementary role of copeptin and highsensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail, 2011, 13, 726-33.
35. Dieplinger B., Gegenhuber A., Haltmayer M., Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart, 2009, 95, 1508-13.
36. Miller W.L., Hartman K.A., Grill D.E., Struck J., Bergmann A., Jaffe A.S. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure, incremental prognostic value of novel biomarkers in heart failure. Heart, 2012, 98, 389-94.